Chemistry Analyzer Complements Augments Escalon's Suite of Hematology
                                  Products

    WAYNE, Pa., July 17 /PRNewswire-FirstCall/ -- Escalon Medical Corp.
(Nasdaq: ESMC) announced today that its Drew Scientific business unit
received 510(k) clearance from the U.S. Food and Drug Administration (FDA)
to market the new TRILOGY Analyzer. TRILOGY, a multifunction analyzer used
in determination of analytes in body fluids, is an open system intended for
clinical use in a professional setting for use with various chemistry
assays. The analyzer is currently on display at the 2007 AACC Annual
Meeting and Clinical Lab Expo held in San Diego, CA. Drew Scientific plans
to commence shipments of the product in the United States immediately.
    "We are excited about broadening our product portfolio and having FDA
clearance of the new multi-purpose analyzer in time for the opening of the
AACC conference this week," commented Richard J. DePiano, Chairman and
Chief Executive Officer. "The TRILOGY system augments our existing
hematology base business providing Drew Scientific with the ability to
offer turnkey solutions in both chemistry and hematology."
    TRILOGY was designed for the quantitative determination of glucose,
creatinine and urea nitrogen in serum. Glucose measurements are used in the
diagnosis and treatment of carbohydrate metabolism disorders including
diabetes mellitus, neonatal hypoglycemia and idiopathic hypoglycemia, and
of pancreatic islet call carcinoma. Creatinine measurements are used in the
diagnosis and treatment of renal diseases and in monitoring renal dialysis.
Urea nitrogen measurements are used in the diagnosis and treatment of
certain renal and metabolic diseases. TRILOGY includes an optional Ion
Selective Electrodes (ISE) module for the measurement of sodium, and
chloride in serum and urine. These measurements are used to monitor
electrolyte balance and in the diagnosis and treatment of diseases
involving electrolyte imbalance.
    Drew Scientific is a diagnostics company specializing in the design,
manufacture and distribution of instruments for blood cell counting and
blood analysis. Drew Scientific is focused on providing instrumentation and
consumables for the physician office and veterinary office laboratories.
Drew Scientific also supplies the reagent and other consumable materials
needed to operate the instruments.
    Founded in 1987, Escalon develops markets and distributes ophthalmic
diagnostic, surgical and pharmaceutical products as well as vascular access
devices. Drew Scientific, which operates as a separate business unit,
provides instrumentation and consumables for the diagnosis and monitoring
of medical disorders in the areas of diabetes, cardiovascular diseases and
hematology, as well as veterinary hematology and blood chemistry. Escalon
seeks to utilize strategic partnerships to help finance its development
programs and is also seeking acquisitions to further diversify its product
line to achieve critical mass in sales and take better advantage of
Escalon's distribution capabilities, although any such partnerships or
acquisitions may not occur. Escalon has headquarters in Wayne, Pennsylvania
and manufacturing operations in Long Island, New York, New Berlin,
Wisconsin, Dallas, Texas, Oxford, Connecticut and Barrow-in-Furness, U.K.
    Note: This press release contains statements that are considered
forward- looking under the Private Securities Litigation Reform Act of
1995, including statements about Escalon's future prospects. They are based
on Escalon's current expectations and are subject to a number of
uncertainties and risks, and actual results may differ materially. The
uncertainties and risks include whether Escalon is able to:
    -- implement its growth and marketing strategies, improve upon the
       operations of Escalon's business units, including the integration of
       Drew Scientific's and MRP's operations, the reorganization of the Drew
       Scientific's business and the integration of any acquisitions it may
       undertake, if any, of which there can be no assurance;
    -- implement cost reductions;
    -- generate cash; and
    -- identify, finance and enter into business relationships and
       acquisitions.

    Other factors include uncertainties and risks related to:
    -- new product development, commercialization, manufacturing, product
       liability and market acceptance of new products,
    -- marketing acceptance of existing products in new markets, the
       continuity of royalty revenue, litigation and non-recurring expenses;
    -- research and development activities, including failure to demonstrate
       clinical efficacy;
    -- delays by regulatory authorities, scientific and technical advances by
       Escalon or third parties;
    -- introduction of competitive products;
    -- third party reimbursement and physician training, and
    -- general economic conditions.
    Further information about these and other relevant risks and
uncertainties may be found in the Company's report on Form 10-K, and its
other filings with the Securities and Exchange Commission, all of which are
available from the Commission as well as other sources.

Link to this page: